Parkinson's Disease (PD) Drugs Market Key Highlights:
- Market Size (2024): USD 6.02 Billion
- Projected Market Size (2034): USD 9.26 Billion
- CAGR (2023-2034): 4.4%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Parkinson's Disease (PD) Drugs Market Definition
The Parkinson’s disease drugs market.is going to be increasingly saturated. New product introductions and several therapeutics coming into the product portfolios of global pharmaceutical companies are adding to the mobility of the market. Parkinson's is a chronic movement disorder, a progressive neurological condition that especially occurs in the elderly through the gradual loss of neurons in some areas of the brain that are involved in producing the type and amount of dopamine required for smooth control of movement. It is caused because the brain produces less dopamine which leads to problems like tremors, stiffness, difficulties in walking, etc.
Consumption of products for Parkinson’s disease is expected to rise during the forecast period since the geriatric population across the world is expected to rise. In addition, key players are inclined toward enhancing their spending on R&D associated with Parkinson’s disease drugs because of the growing geriatric populace that acts as a driver for the Parkinson’s disease drugs market. However, there are side effects that are related to the Parkinson’s disease drugs which constrain the market progress. On the other hand, high growth in unpenetrated emerging countries and more number of R&D pipeline products promise to provide good growth opportunities for Parkinson’s disease drugs to the key players. More than 1.2 million Europeans live with Parkinson’s disease, a figure that the European Parkinson’s Disease Association estimates will double by 2030.
Parkinson's Disease (PD) Drugs Market Segmentation:
By Type
- Dopamine Agonist
- Monoamine Oxidase Inhibitors
- Acetylcholinesterase Inhibitors
- Glutamate Inhibitors
By Application
Parkinson's Disease (PD) Drugs Market Companies:
- Boehringer Ingelheim
- GlaxoSmithKline
- Novartis
- Teva Pharmaceutical Industries
- AbbVie
- Abital Pharma
- Addex Therapeutics
- Biogen
- Eisai
- Eli Lilly
- F. Hoffmann-La Roche
- H. Lundbeck
- Impax Laboratories
- Kyowa Hakko Kirin
- Otsuka Pharmaceutical
- Pfizer.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
